Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valera's Vantas Prostate Cancer Implant To Launch By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

Valera is assembling a 50-rep urology sales force and building inventory for histrelin. Company hopes to distinguish Vantas from the other 12-month implant, Bayer/Alza's Viadur, based on the design of the delivery system.

You may also be interested in...



Indevus Gains Supprelin LA With Purchase Of Valera

Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.

Indevus Gains Supprelin LA With Purchase Of Valera

Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.

J&J Viadur Promotional Aid Omits Risk Information, FDA Warning Letter Says

A patient disc puzzle includes no risk information, FDA said. The promotion's references to Viadur's website and toll-free number do not satisfy risk disclosure requirements.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel